CAJ | 학술논문

目的观察咖啡酸(CFA)对伊马替尼致慢性粒细胞白血病(CML)患者血小板、白细胞减少的临床疗效和患者不良反应.方法对42例应用伊马替尼治疗后出现血小板、白细胞减少的CML患者,血小板和(或)白细胞减少时即开始应用CFA,0.2 g/次,3次/d,口服,观察治疗过程中血小板、白细胞变化情况和患者不良反应.结果治疗血小板减少42例,其中显效21例,良效13例,无效8例,总有效率81.0 ％(34/42)；治疗白细胞减少28例,其中显效15例,良效8例,无效5例,总有效率82.1％(23/28);治疗第2周时血小板、白细胞计数与治疗前相比差异有统计学意义(t=2.015,P=0.023;t=1.913,P=0.035)；CFA治疗有效患者的平均起效时间为2周.未发现治疗相关不良反应.结论 CFA治疗伊马替尼所致的CML患者血小板、白细胞减少疗效确切,无明显不良反应,是CML治疗过程中安全有效的辅助治疗药物.
목적 관찰가배산(CFA)대이마체니치만성립세포백혈병(CML)환자혈소판、백세포감소적림상료효화환자불량반응.방법 대42례응용이마체니치료후출현혈소판、백세포감소적CML환자,혈소판화(혹)백세포감소시즉개시응용CFA,0.2 g/차,3차/d,구복,관찰치료과정중혈소판、백세포변화정황화환자불량반응.결과 치료혈소판감소42례,기중현효21례,량효13례,무효8례,총유효솔81.0 ％(34/42)；치료백세포감소28례,기중현효15례,량효8례,무효5례,총유효솔82.1％(23/28);치료제2주시혈소판、백세포계수여치료전상비차이유통계학의의(t=2.015,P=0.023;t=1.913,P=0.035)；CFA치료유효환자적평균기효시간위2주.미발현치료상관불량반응.결론 CFA치료이마체니소치적CML환자혈소판、백세포감소료효학절,무명현불량반응,시CML치료과정중안전유효적보조치료약물.
Objective To investigate the curative effect and adverse reaction of caffeic acid (CFA) for leukopenia and thrombocytopenia caused by imatinib in chronic myeloid leukemia (CML) patients.Methods The effect and adverse reactions of CFA for leukopenia or thrombocytopenia induced by imatinib in 42 CML patients were observed.The CFA was admitted by 0.2 g/time,3 times/d,oral.Results 21 cases of 42 CML patients with thrombocytopenia achieved remarkable curative effect after CFA treatment,13 achieved good effect and 8 had no effect.The total effective rate was 81.0 ％ (34/42).While 15 of 28 leukopenia CML patients achieved remarkable curative effect,8 achieved good effect and 5 had no effect.The total effective rate was 82.1％ (23/28).After CFA therapy for 2 weeks,both platelet and white blood cells count were elevated compared with before treatment,the differences were statistically significant (t =2.015,P =0.023,t =1.913,P =0.035).The average onset time of CFA for leukopenia and thrombocytopenia was 2 weeks and no treatment-related adverse reaction was found.Conclusion CFA is an effective and safe auxiliary drug for treatment of imatinib-induce leukopenia and thrombocytopenia in patients with CML.